Skip to main content
TipRanks
Go Ultimate75% OFF

Lineage Therap (LCTX) AI Stock Analysis

2,101 Followers
LCTX

Lineage Therap

(NYSE MKT:LCTX)

Select Model
Rating:48Neutral
Price Target:$0.79â–¼(-1.01% Downside)
Action:reiterated
Date:11/17/26

The score is held down primarily by weak financial performance (ongoing operating losses and cash burn, plus a recent TTM revenue decline) and bearish technicals (below major moving averages with negative MACD). These are partially offset by a constructive earnings-call outlook—pipeline expansion via the NeuroAirmid/HUNT1 acquisition, external trial funding, and runway guidance into Q2 2028—though valuation support is limited given the very high P/E and no dividend yield.

Positive Factors
Pipeline ExpansionAdding HUNT1 broadens Lineage's clinical portfolio into Huntington's disease while leveraging its allogeneic cell-therapy focus. A third clinical-stage asset creates more opportunities for clinical validation, partnerships, and eventual milestone or royalty revenue across distinct neurological and ophthalmology markets.
Negative Factors
Persistent Cash BurnContinued negative operating and free cash flow shows that Lineage's activities are consuming cash rather than funding themselves. Even with a low-debt balance sheet, ongoing burn can reduce financial flexibility and eventually require additional financing if programs continue expanding.

Lineage Therap (LCTX) vs. SPDR S&P 500 ETF (SPY)

-60%-50%-40%-30%-20%-10%0%10%20%LCTX-52.40%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$201.12M
Dividend Yield
―
Average Volume (3M)
1.53M
Price to Earnings (P/E)
128.3
Beta (1Y)
1.01
Revenue Growth
0.18%
EPS Growth
―
Country
US
Employees
75
Sector
General
Sector Strength
55
Industry
Biotechnology

Lineage Therap Business Overview & Revenue Model

Company Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment e...

How the Company Makes Money

Lineage primarily makes money through (1) collaboration and license-related revenue and (2) raising capital, rather than through product sales, because it is a clinical-stage company without broadly commercialized products. Collaboration/licensing ec...

Lineage Therap Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-19.70%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call was strongly optimistic, centered on the transformational NeuroAirmid acquisition, the addition of HUNT1 as a third clinical-stage asset, positive preclinical findings, early safety observations, external trial funding, manufacturing capabilities, and an extended cash runway. The company also reported progress across ILT1, COR1, ReSonance, OpRegen, and OPC1. Offsetting factors included lower revenue, higher operating expenses, a wider operating loss, uncertainty over partner-controlled OpRegen timing, and the early stage of HUNT1 clinical and manufacturing validation. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Transformational NeuroAirmid Acquisition Adds HUNT1
Lineage acquired NeuroAirmid Therapeutics and secured HUNT1, formerly known as hNSC-01, a clinical-stage allogeneic neural progenitor cell therapy for Huntington's disease. HUNT1 is currently being evaluated in the Phase Ib/IIa REGEN4HD study and becomes Lineage's third clinical-stage asset alongside OpRegen and OPC1.

Negative Updates

Third-Quarter Revenue Declined
Total revenue for the three months was approximately $1.5 million, a net decrease of $2.2 million from $3.7 million in the same period of 2025. The decline was primarily due to lower collaboration revenue recognized under the Roche agreement and lower revenue from the WDI research collaboration, with both decreases driven by fewer services provided in the current year.

Company Guidance

Management updated run rate guidance into Q2 2028, which is 1 quarter earlier than prior guidance, and said $45.2 million in cash, cash equivalents and marketable securities as of September 30, 2026, is expected to fund planned operations into the second quarter of 2028; REGEN4HD clinical costs are estimated to run less than $2 million per year within a historic budget run rate of approximately $30 million per year, with up to approximately $2.6 million in cash, $2.4 million worth of Lineage common shares and a $356,000 cash payment due on the first anniversary of closing; Lineage remains eligible for approximately $32 million from warrants with a strike price of $0.91 and up to $615 million in development and commercial milestone payments; COR1 initial preclinical data are expected internally by year-end and publicly in the first quarter of 2027, ReSonance’s scientific advice meeting is scheduled for December, the third OPC1 DOSED patient is scheduled for surgery before year-end and a fourth patient is expected to be dosed in Q1, and the 21-patient Phase Ib/IIa REGEN4HD trial is currently enrolling.

Lineage Therap Financial Statement Overview

Summary

Overall financial quality is constrained by persistent operating losses and ongoing cash burn (negative operating and free cash flow), even as the balance sheet is conservatively levered with low debt. High gross margins are a positive, but recent TTM revenue decline and the mismatch between TTM net income and negative cash flow point to earnings quality risk.

Income Statement

34Negative

Balance Sheet

72Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue10.84M14.56M9.50M8.95M14.70M3.90M
Gross Profit10.39M13.71M9.16M8.27M13.97M2.47M
EBITDA-2.16M-67.95M-17.97M-22.59M-25.09M-42.40M
Net Income1.75M-63.53M-18.61M-21.49M-26.27M-43.02M
Balance Sheet
Total Assets100.11M112.58M113.22M101.02M123.66M174.54M
Cash, Cash Equivalents and Short-Term Investments45.18M55.78M47.80M35.49M57.88M58.36M
Total Debt2.03M2.42M2.51M2.95M3.90M2.80M
Total Liabilities34.17M69.24M36.21M39.00M51.73M83.65M
Stockholders Equity67.06M44.55M78.38M63.42M73.34M92.22M
Cash Flow
Free Cash Flow-26.00M-19.44M-23.66M-29.24M646.00K-23.91M
Operating Cash Flow-25.82M-18.92M-23.09M-28.57M1.06M-23.56M
Investing Cash Flow-18.85M-13.46M-2.31M46.45M-46.16M9.74M
Financing Cash Flow30.38M26.95M35.86M6.42M1.63M36.93M

Lineage Therap Technical Analysis

Technical Analysis SentimentNegative
Last Price0.80

Price Trends

50DMA0.99Negative
100DMA1.07Negative
200DMA1.29Negative

Market Momentum

MACD-0.01Positive
RSI34.03Neutral
STOCH10.78Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LCTX, the sentiment is Negative. The current price of 0.80 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 0.99, and below the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.03 is Neutral, neither overbought nor oversold. The STOCH value of 10.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LCTX.

Lineage Therap Risk Analysis

Lineage Therap disclosed 79 risk factors in its most recent earnings report. Lineage Therap reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our largest shareholder, who is affiliated with a member of our board of directors, owns a significant percentage of our common shares and will be able to exert substantial influence over the election of directors and matters subject to shareholder approval, including potential change of control transactions.Q4, 2025
2.We may fail to enter into new strategic relationships or may not realize the benefits of any strategic relationships that we have entered into, either of which could materially adversely affect our business, financial condition, commercialization prospects, and results of operations.Q4, 2025
3.Our decisions regarding whether to advance our programs internally or through strategic relationships may not maximize the value of our pipeline for our shareholders, and misjudgments in these decisions could materially adversely affect our business.Q4, 2025

Lineage Therap Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

LCTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
AMRNAMRN50Neutral$238.43M-10.77-4.26%―-22.43%78.01%
LCTXLCTX48Neutral$201.12M128.293.10%―0.18%―
DBVTDBVT47Neutral$646.80M-3.43-121.83%――42.37%
TVRDTVRD47Neutral$14.70M-0.42-179.86%―-100.00%67.96%
FDMTFDMT45Neutral$623.71M-4.08-47.06%―79952.50%29.07%
AURAAURA41Neutral$751.42M-4.31-64.69%――13.33%

* General Sector Average

Performance Comparison

-50%0%50%LCTXAMRNTVRDDBVTFDMTAURADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LCTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LCTXLineage Cell Therapeutics, Inc.0.80-0.91-53.51%
AMRNAmarin Corporation Plc11.31-5.67-33.39%
TVRDTvardi Therapeutics Inc.1.10-2.83-72.01%
DBVTDBV Technologies S.A. - American Depositary Shares10.27-4.03-28.18%
FDMT4D Molecular Therapeutics, Inc.11.290.494.54%
AURAAura Biosciences Inc7.221.8233.70%

Lineage Therap Corporate Events

Business Operations and StrategyM&A TransactionsProduct-Related AnnouncementsRegulatory Filings and Compliance

Lineage Therapeutics Acquires NeuroAirmid, Expanding Cell Therapy Pipeline

Positive
Nov 12, 2026

On November 12, 2026, Lineage acquired all outstanding shares of NeuroAirmid Therapeutics, making it a wholly owned subsidiary and adding HUNT1, a pluripotent stem cell-derived neural cell therapy for Huntington’s disease. HUNT1 was being evaluated i...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026